Savella: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(create)
 
m (outline)
Line 1: Line 1:
'''Savella''' or '''milnacipran''' (generic name) is an antidepressant that is also licensed for use in [[fibromyalgia]]. No studies have been carried out on the effectiveness of Savella in [[ME/CFS]] patients, although off-label use of psychiatric medications in ME/CFS has generally been ineffective.<ref name="Kim2020">{{Cite journal|last=Kim|first=Do-Young|author-link=|last2=Lee|first2=Jin-Seok|author-link2=|last3=Park|first3=Samuel-Young|author-link3=|last4=Kim|first4=Soo-Jin|author-link4=|last5=Son|first5=Chang-Gue|author-link5=|date=2020-01-06|title=Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)|url=https://doi.org/10.1186/s12967-019-02196-9|journal=Journal of Translational Medicine|volume=18|issue=1|pages=1-12|doi=10.1186/s12967-019-02196-9|issn=1479-5876|pmc =  6943902|pmid=31906979|access-date=|quote=|via=}}</ref>
'''Savella''' or '''milnacipran''' (generic name) is an antidepressant that is also licensed for use in [[fibromyalgia]]. No studies have been carried out on the effectiveness of Savella in [[ME/CFS]] patients, although off-label use of psychiatric medications in ME/CFS has generally been ineffective.<ref name="Kim2020">{{Cite journal|last=Kim|first=Do-Young|author-link=|last2=Lee|first2=Jin-Seok|author-link2=|last3=Park|first3=Samuel-Young|author-link3=|last4=Kim|first4=Soo-Jin|author-link4=|last5=Son|first5=Chang-Gue|author-link5=|date=2020-01-06|title=Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)|url=https://doi.org/10.1186/s12967-019-02196-9|journal=Journal of Translational Medicine|volume=18|issue=1|pages=1-12|doi=10.1186/s12967-019-02196-9|issn=1479-5876|pmc =  6943902|pmid=31906979|access-date=|quote=|via=}}</ref>


==References ==
==Theory==
{{Reflist}}
 
==Evidence==
Savella is an FDA-approved drug for [[fibromyalgia]], with improvements in [[pain]], [[sleep dysfunction|sleep]] and more limited improvements in [[fatigue]].
 
No clinical trials have been done for Savella/milnacipran in [[ME/CFS]].
 
==Clinicians==
 
==Risks and safety==
 
==Costs and availability==
Perscription only drug.
 
==Notable studies ==
 
 
==See also==
 
==Learn more==
*
 
==References==
{{reflist}}


[[Category:Antidepressants]]
[[Category:Potential treatments]]
[[Category:Potential treatments]]
[[Category:Serotonin-norepinephrine reuptake inhibitors]]
[[Category:Analgesics]]
[[Category:Analgesics]]
[[Category:Antidepressants]]

Revision as of 16:41, January 17, 2022

Savella or milnacipran (generic name) is an antidepressant that is also licensed for use in fibromyalgia. No studies have been carried out on the effectiveness of Savella in ME/CFS patients, although off-label use of psychiatric medications in ME/CFS has generally been ineffective.[1]

Theory[edit | edit source]

Evidence[edit | edit source]

Savella is an FDA-approved drug for fibromyalgia, with improvements in pain, sleep and more limited improvements in fatigue.

No clinical trials have been done for Savella/milnacipran in ME/CFS.

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Perscription only drug.

Notable studies[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. Kim, Do-Young; Lee, Jin-Seok; Park, Samuel-Young; Kim, Soo-Jin; Son, Chang-Gue (January 6, 2020). "Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)". Journal of Translational Medicine. 18 (1): 1–12. doi:10.1186/s12967-019-02196-9. ISSN 1479-5876. PMC 6943902. PMID 31906979.